Warning letter
GAR Laboratories Inc [ARCHIVED]: warning letter of Dec 6, 2010
FDA warning letter 132170 · Los Angeles District Office
Key facts
| Reference number | 132170 |
|---|---|
| Company | GAR Laboratories Inc [ARCHIVED] |
| Subject | CGMP/Finished Products/Adulterated |
| Issue date | Dec 6, 2010 |
| Posted date | Dec 6, 2010 |
| Issuing office | Los Angeles District Office |
| Product type | Drugs |
| CFR sections cited | 211.180(e)(2), 211.63, 211.100, 211.192, 211.22(a), 211.22(c), 211.67(b), 211.115(a), 211.142(b), 211.160(b), 211.166(a), 211.194(a) and 1 more |
| Inspection city | Riverside |
| Inspection ZIP | 92507 |
| Inspection start date | Jul 13, 2010 |
| Letter on fda.gov | web.archive.org |
At a glance
- 10–99 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: